MedTrace Logo

Early Intervention Strategies for Lung Cancer

NCT06988943 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16000

Last updated 2025-05-30

No results posted yet for this study

Summary

Low-dose CT (LDCT）can detect and treat lung cancer earlier and more quickly, while expanded screening coverage helps reduce the incidence and mortality of respiratory diseases such as lung cancer. This study aims to conduct a single-arm cluster randomized trial of digitally enabled LDCT in Guangzhou to assess its intervention effectiveness and cost-effectiveness.

Conditions

  • Respiratory Tract Neoplasms
  • Thoracic Neoplasms
  • Neoplasms by Site
  • Neoplasms
  • Lung Diseases
  • Respiratory Tract Diseases
  • Lung Neoplasms

Interventions

DEVICE

Low-dose CT screening

Low-dose CT screening is conducted at primary healthcare institutions, and patients with detected lung nodules are referred to hospitals for further examination

DEVICE

AI full-lung model interpretation system

Using artificial intelligence technology to assist in the interpretation of CT images

DEVICE

Digital Health Platform

Community health centers and streets in Guangzhou use a program called "Fei Anxin" to manage residents' information in a unified way

Sponsors & Collaborators

  • The First Affiliated Hospital of Guangzhou Medical University

    lead OTHER

Principal Investigators

  • Jianxing He, MD · Department of Cardiothoracic Surgery, the First Affiliated Hospital of Guangzhou Medical College

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-06-25
Primary Completion
2025-06-30
Completion
2025-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06988943 on ClinicalTrials.gov